A study investigating the potential association between the use of angiotensin-receptor blockers (ARBs) and ACE inhibitors and the risk of COVID-19 showed that this use was more frequent among patients who were infected with SARS-CoV-2 than among the large number of controls who were matched by age, sex, and place of residence, providing evidence that the use of ARBSs or ACE inhibitors was independently associated with the risk of COVID-19 in patients with mild-to-moderate disease or those with severe disease [22]. This evidence concerns the gene ACE and COVID-19.